Study Evaluation Tazocin Intervention

Phase 4

Completed

• Conditions: Bacterial Infections
• Interventions: Drug: Tazocin (pipercillin/tazobactam)

• Registration Number: NCT00488189
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

This is an antibiotic intervention study to determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05
• Study First Submitted: 2007-06-18
• Study First Submitted QC: 2007-06-18
• Study First Posted: 2007-06-20
• Primary Completion: 2008-02
• Study Completion: 2008-02
• Status Verified: 2010-06
• Last Update Submitted: 2011-04-14
• Last Update Posted: 2011-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 134

Inclusion Criteria

• All patients admitted or transferred to ICU/Pulmonary units
• Patients of either sex, 18 years of age or older

Exclusion Criteria

• Patients who stay in units less than 48 hours will not be enrolled.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
2	Tazocin (pipercillin/tazobactam)	use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab

Primary Outcome Measures

Name	Time	Method
1. The acquisition rate of ESBL producing E. coli or K. Pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months of intervention phase)	9 months

Secondary Outcome Measures

Name	Time	Method
The infection rate due to ESBL producing E. coli or K. pnumoniae at the end of phase I (pre-intervention) and phase II (last 3 months of intervention phase)	9 months